# TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ

> **NIH NIH N01** · A AND G PHARMACEUTICAL, INC. · 2024 · $16,463

## Abstract

NCATS needs Monoclonal antibodies for bioanalytical method development for expression, toxicokinetic and pharmacokinetic studies and immunogenicity assessment of AAV8-COLQ, a platform-based gene therapy drug candidate for the treatment of Congenital Myasthenic Syndrome (CMS). This task order defines the tasks which will be undertaken to produce  monoclonal cell lines that generate antibodies with affinity to either the PRAD domain of COLQ or the Human epitope of Human COLQ, and purified monoclonal antibody preparations for this project and documentation suitable for use of these antibody preparations in regulated preclinical and clinical assays.

## Key facts

- **NIH application ID:** 11042690
- **Project number:** 271201800010I-P00001-759502300001-1
- **Recipient organization:** A AND G PHARMACEUTICAL, INC.
- **Principal Investigator:** AKIVA KOSOWSKY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $16,463
- **Award type:** —
- **Project period:** 2023-09-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11042690

## Citation

> US National Institutes of Health, RePORTER application 11042690, TO6 - GENERATING MONOCLONAL CELL LINES, MONOCLONAL ANTIBODIES, AND LABELED MONOCLONAL ANTIBODIES AGAINST HUMAN AND MOUSE COLQ (271201800010I-P00001-759502300001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11042690. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*